Predictive Value of Heart Rate in Treatment of Major Depression with Ketamine in Two Controlled Trials

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023752%3A_____%2F21%3A43920534" target="_blank" >RIV/00023752:_____/21:43920534 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11120/21:43921421

Výsledek na webu

<a href="https://www.sciencedirect.com/science/article/pii/S138824572100081X?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S138824572100081X?via%3Dihub</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.clinph.2021.01.030" target="_blank" >10.1016/j.clinph.2021.01.030</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Predictive Value of Heart Rate in Treatment of Major Depression with Ketamine in Two Controlled Trials

Popis výsledku v původním jazyce

Objective: Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD). This controlled study aimed to analyse the predictive and discriminative power of heart rate (HR) and heart rate variability (HRV) for ketamine treatment in MDD. Methods: In 51 patients, HR and HRV were assessed at baseline before and during ketamine infusion and 24 hours post ketamine infusion. Montgomery–Åsberg Depression Rating Scale (MADRS) was used to assess changes of depressive symptoms. A 30% or 50% reduction of symptoms after 24 hours or within 7 days was defined as response. A linear mixed model was used for analysis. Results: Ketamine infusion increased HR and HRV power during and after infusion. Responders to ketamine showed a higher HR during the whole course of investigation, including at baseline with medium effect sizes (Cohen‘s d=0.47-0.67). Furthermore, HR and HRV power discriminated between responders and non-responders, while normalized low and high frequencies did not. Conclusion: The findings show a predictive value of HR and HRV power for ketamine treatment. This further underlines the importance of the autonomous nervous system (ANS) and its possible malfunctions in MDD. Significance: The predictive power of HR and HRV markers should be studied in prospective studies. Neurophysiological markers could improve treatment for MDD via optimizing the choice of treatments.

Název v anglickém jazyce

Predictive Value of Heart Rate in Treatment of Major Depression with Ketamine in Two Controlled Trials

Popis výsledku anglicky

Objective: Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD). This controlled study aimed to analyse the predictive and discriminative power of heart rate (HR) and heart rate variability (HRV) for ketamine treatment in MDD. Methods: In 51 patients, HR and HRV were assessed at baseline before and during ketamine infusion and 24 hours post ketamine infusion. Montgomery–Åsberg Depression Rating Scale (MADRS) was used to assess changes of depressive symptoms. A 30% or 50% reduction of symptoms after 24 hours or within 7 days was defined as response. A linear mixed model was used for analysis. Results: Ketamine infusion increased HR and HRV power during and after infusion. Responders to ketamine showed a higher HR during the whole course of investigation, including at baseline with medium effect sizes (Cohen‘s d=0.47-0.67). Furthermore, HR and HRV power discriminated between responders and non-responders, while normalized low and high frequencies did not. Conclusion: The findings show a predictive value of HR and HRV power for ketamine treatment. This further underlines the importance of the autonomous nervous system (ANS) and its possible malfunctions in MDD. Significance: The predictive power of HR and HRV markers should be studied in prospective studies. Neurophysiological markers could improve treatment for MDD via optimizing the choice of treatments.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30215 - Psychiatry

Projekt

Výsledek vznikl pri realizaci vícero projektů. Více informací v záložce Projekty.

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Neurophysiology

ISSN

1388-2457

e-ISSN

—

Svazek periodika

132

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

8

Strana od-do

1339-1346

Kód UT WoS článku

000653018000023

EID výsledku v databázi Scopus

2-s2.0-85106084719